Related Experiment Videos
Crohn's disease: step up or top down therapy.
1University of Chicago, 5841 S Maryland Ave, MC4076, Chicago, Il 60637, USA.
Best Practice & Research. Clinical Gastroenterology
|March 6, 2003
Summary
The study explores early aggressive treatment versus sequential therapy for Crohn's disease, considering novel anti-tumour necrosis factor (TNF) therapies. It weighs the benefits and risks of these approaches for managing the inflammatory bowel disease.
Area of Science:
- Gastroenterology and immunology
- Inflammatory bowel disease research
- Therapeutic strategy development
Background:
- The evolution of Crohn's disease treatment strategies is influenced by novel anti-tumour necrosis factor (TNF) therapies.
- Anti-TNF agents offer potential mucosal healing with fewer systemic complications compared to glucocorticoids, sparking debate on treatment intensity.
- Current treatment paradigms are shifting towards sequential therapy for remission induction and maintenance, preceding definitive disease modification criteria.
Purpose of the Study:
- To evaluate the evidence for therapeutic efficacy in Crohn's disease.
- To analyze the benefits and risks associated with early aggressive treatment versus sequential therapeutic approaches.
- To inform clinical decision-making regarding the optimal management strategy based on disease severity.
Main Methods:
- Review of existing evidence on the efficacy of anti-TNF therapies in Crohn's disease.
- Comparative analysis of 'step-up' (sequential) versus 'top-down' (early aggressive) treatment strategies.
- Consideration of clinical, pathological, molecular, and genetic factors in predicting disease natural history.
Main Results:
- Novel anti-TNF therapies demonstrate efficacy, particularly in patients refractory to conventional treatments.
- Anti-TNF treatments show potential for mucosal healing without significant glucocorticoid-related systemic side effects.
- The debate on early aggressive therapy is ongoing, lacking definitive criteria for disease modification or natural history prediction.
Conclusions:
- The choice between early aggressive and sequential therapy for Crohn's disease requires careful consideration of treatment benefits and risks.
- Further research is needed to establish clear criteria for predicting Crohn's disease natural history and guiding therapeutic decisions.
- Optimizing Crohn's disease management necessitates a nuanced approach that balances efficacy with potential adverse effects.